BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months
Osteoporosis clinical trials and catalysts
Active industry-sponsored trials on ClinicalTrials.gov for osteoporosis: 29 (21 sponsors; 2 newly posted in the last 180 days, 0 stopped in the last 180 days; 1 new-entrant sponsors). Momentum score 12.1, rank 58 of 91 on the disease-area ranking. As of 2026-11-18.
Phase distribution: Early Phase 1 0, Phase 1 2, Phase 2 3, Phase 3 3, Phase 4 3, N/A 18.
Most active sponsors, by phase
| Sponsor | Active trials | By phase | New (window) | Upcoming readouts |
|---|---|---|---|---|
| Qilu Pharmaceutical Co., Ltd. | 2 | P3 2 | 0 | 2 |
| Luye Pharma Group Ltd. | 1 | P3 1 | 0 | 0 |
| AgNovos Healthcare, LLC | 4 | NA 4 | 0 | 2 |
| Amber Implants B.V. | 3 | NA 3 | 1 | 0 |
| Amgen AMGN | 2 | P4 2 | 0 | 2 |
| Shenzhen Salubris Pharmaceuticals Co., Ltd. | 2 | P1 1, P2 1 | 0 | 0 |
| Angitia Biopharmaceuticals | 1 | P2 1 | 0 | 1 |
| Bespoke Clinical Research | 1 | NA 1 | 0 | 0 |
| Blueprint Medicines Corporation | 1 | NA 1 | 0 | 0 |
| HELP Therapeutics Co., Ltd. | 1 | P1 1 | 0 | 0 |
| Inossia AB | 1 | NA 1 | 0 | 0 |
| Insud Pharma | 1 | P4 1 | 0 | 0 |
| Paola Pisani | 1 | NA 1 | 0 | 0 |
| POROUS GmbH | 1 | NA 1 | 0 | 0 |
| Precision IO Group DTIL | 1 | NA 1 | 0 | 1 |
| Promedius Inc | 1 | NA 1 | 0 | 1 |
| Relation Therapeutics | 1 | NA 1 | 0 | 0 |
| Solarea Bio, Inc | 1 | NA 1 | 0 | 1 |
| Transcenta Therapeutics (Hangzhou) Co., Ltd. new entrant | 1 | P2 1 | 1 | 1 |
| Ufonia | 1 | NA 1 | 0 | 0 |
| Universal Integrated Corp. | 1 | NA 1 | 0 | 0 |
New-entrant sponsors: Transcenta Therapeutics (Hangzhou) Co., Ltd..
Upcoming trial readouts (next 90 days)
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|---|---|---|---|---|---|
| 2026-12 est. | P2 | Angitia Biopharmaceuticals | NCT06577935 A Trial Evaluating Efficacy of AGA2118 in PostMenopausal Women wIth Low Bone MasS (ARTEMIS) | Postmenopausal Osteoporosis | active not recruiting | 379 |
| 2027-01 est. | P3 | Qilu Pharmaceutical Co., Ltd. | NCT07062978 A Comparative Study to Valuating the Efficacy and Safety of QL1206 and Prolia® | Postmenopausal Women With Osteoporosis at High Risk of Fracture | recruiting | 278 |
Readouts in the last 180 days
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|---|---|---|---|---|---|
| 2026-07-30 est. | P2 | Shenzhen Salubris Pharmaceuticals Co., Ltd. | NCT07579936 A Phase II Clinical Trial of the Safety and Efficacy of SAL056 at Different Doses and Dosing Regimens | Postmenopausal Women With Osteoporosis | recruiting | 200 |
Landscape counts: ClinicalTrials.gov, industry lead sponsors, active statuses, via the free hosted BioCatalystFeed MCP tool condition_landscape (query "osteoporosis"); readouts matched by condition text. Registry counts only; not a forecast.
Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line
results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are
company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA
(openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score.
Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP
readout_calendar / fda_decisions. Not investment advice.